Abstract | PURPOSE OF REVIEW: Few standard second-line treatment options exist for advanced sarcoma patients. Some of these patients are offered early-phase clinical trials involving targeted or nontargeted agents. This review outlines recent phase 1 trials involving sarcoma patients, explores current challenges and highlights future opportunities in sarcoma developmental therapeutics. RECENT FINDINGS: SUMMARY: Patients with refractory sarcoma demonstrate benefit from treatment with targeted drugs even in the setting of phase 1 trials. Sarcomas that have a defined translocation and those that express specific activated kinases are particularly promising tumors for targeted therapy. The primary challenge is identifying the biomarkers predictive of response or resistance, matching them with specific patient histology, resulting in successful translation of biology into clinical benefit.
|
Authors | Vivek Subbiah, Razelle Kurzrock |
Journal | Current opinion in oncology
(Curr Opin Oncol)
Vol. 23
Issue 4
Pg. 352-60
(Jul 2011)
ISSN: 1531-703X [Electronic] United States |
PMID | 21519259
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
|
Chemical References |
- Antibodies, Monoclonal
- Antineoplastic Agents
- Protein Kinase Inhibitors
|
Topics |
- Antibodies, Monoclonal
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Bone Neoplasms
(drug therapy)
- Clinical Trials, Phase I as Topic
- Humans
- Molecular Targeted Therapy
- Prognosis
- Protein Kinase Inhibitors
(therapeutic use)
- Sarcoma
(drug therapy)
|